Administration of Bacteriophages via Nebulization during Mechanical Ventilation: In Vitro Study and Lung Deposition in Macaques
Authors:
- Sandrine Le GuellecSGSandrine Le Guellec
- Jeoffrey PardessusJPJeoffrey Pardessus
- Elsa Bodier-MontagutelliEBElsa Bodier-Montagutelli
- Guillaume L’hostisGLGuillaume L’hostis
- Emilie DalloneauEDEmilie Dalloneau
- Damien PielDPDamien Piel
- Hakim Chouky SamaïHSHakim Chouky Samaï
- Antoine GuillonAGAntoine Guillon
- Elvir MujicEMElvir Mujic
- Emmanuelle Guillot-CombeEGEmmanuelle Guillot-Combe
- Stephan EhrmannSEStephan Ehrmann
- Eric MorelloEMEric Morello
Open Access
Abstract
Bacteriophages have been identified as a potential treatment option to treat lung infection in the context of antibiotic resistance. We performed a preclinical study to predict the efficacy of delivery of bacteriophages against Pseudomonas aeruginosa (PA) when administered via nebulization during mechanical ventilation (MV). We selected a mix of four anti-PA phages containing two Podoviridae and two Myoviridae, with a coverage of 87.8% (36/41) on an international PA reference panel. When administered via nebulization, a loss of 0.30–0.65 log of infective phage titers was measured. No difference between jet, ultrasonic and mesh nebulizers was observed in terms of loss of phage viability, but a higher output was measured with the mesh nebulizer. Interestingly, Myoviridae are significantly more sensitive to nebulization than Podoviridae since their long tail is much more prone to damage. Phage nebulization has been measured as compatible with humidified ventilation. Based on in vitro measurement, the lung deposition prediction of viable phage particles ranges from 6% to 26% of the phages loaded in the nebulizer. Further, 8% to 15% of lung deposition was measured by scintigraphy in three macaques. A phage dose of 1 × 109 PFU/mL nebulized by the mesh nebulizer during MV predicts an efficient dose in the lung against PA, comparable with the dose chosen to define the susceptibility of the strain.Keywords
Funding Information
- Direction Générale de l’Armement
This publication has 48 references indexed in Scilit:
- Clinical outcomes of Pseudomonas aeruginosa pneumonia in intensive care unit patientsIntensive Care Medicine, 2013
- Efficacy of High-dose Nebulized Colistin in Ventilator-associated Pneumonia Caused by Multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumanniiAnesthesiology, 2012
- Impact of lyoprotectants for the stabilization of biodegradable nanoparticles on the performance of air-jet, ultrasonic, and vibrating-mesh nebulizersEuropean Journal of Pharmaceutics and Biopharmaceutics, 2012
- BAY41-6551 achieves bactericidal tracheal aspirate amikacin concentrations in mechanically ventilated patients with Gram-negative pneumoniaIntensive Care Medicine, 2011
- Nebulized Ceftazidime and Amikacin in Ventilator-associated Pneumonia Caused by Pseudomonas aeruginosaAmerican Journal of Respiratory and Critical Care Medicine, 2011
- PHAST: A Fast Phage Search ToolNucleic Acids Research, 2011
- Pulmonary Bacteriophage Therapy on Pseudomonas aeruginosa Cystic Fibrosis Strains: First Steps Towards Treatment and PreventionPLOS ONE, 2011
- Bacteriophages Can Treat and PreventPseudomonas aeruginosaLung InfectionsThe Journal of Infectious Diseases, 2010
- Pseudomonas aeruginosa Population Structure RevisitedPLOS ONE, 2009
- Aerosol Deposition in Neonatal VentilationPediatric Research, 2005